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ROCK inhibition has been largely applied as a strategy to treat neurodegenerative
diseases (NDDs) and promising results have been obtained in the recent years. However,
the underlying molecular and cellular mechanisms are not fully understood and different
models have been proposed for neurodegenerative disorders. Here, we aim to review
the current knowledge obtained for NDDs identifying common mechanisms as well
as disease-specific models. In addition to the role of ROCK in different cell types
such as neurons and microglia, we focus on the molecular signaling-pathways which
mediate the beneficial effects of ROCK. Besides canonical ROCK signaling, modulation
of neighboring pathways by non-canonical ROCK-crosstalk is a recurrent pattern in
many NDD-model systems and has been suggested to mediate beneficial effects of
ROCK-inhibition.
Keywords: spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), huntington’s disease (HD),
parkinson’s disease (PD), alzheimer disease (AD), multiple sclerosis (MS), neuroinflammation, microglia
Introduction
An important signaling hub for the regulation of the actin cytoskeleton and myosin-based
contractility is the Rho-kinase (ROCK). Signaling events downstream of ROCK are responsible
for key neuronal processes in axonogenesis, growth cone dynamics, and stability of synapses.
ROCK has a number of downstream targets including profilins and cofilin (via LIM kinase) as
actin-binding proteins as well as myosin light chain phosphatase (MLCP) (Figure 1). Upstream
of ROCK, Rho-GTP or phosphatidylinositol-4,5-bisphosphate (PIP2), and phosphatidylinositol-
(3,4,5)-trisphosphate (PIP3) activate ROCK (reviewed in Tonges et al., 2011). ROCK-activity
mainly acts detrimental on clinically relevant outcomes in neurodegenerative diseases (NDDs).
This has been elucidated in the recent years by a series of in vivo animal studies: Expression of
dominant negative ROCK-isoforms or application of small molecule inhibitors in rodent-models of
several NDDs or diseases with a neurodegenerative component impressively ameliorated disease-
phenotypes in many studies. Thereby, small molecule inhibitors are of special interest because
of their potential translational use in the clinics compared to genetic approaches. Among those,
Y27632 has been extensively used in basic science. However, since now there is only a single
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FIGURE 1 | The ROCK-pathway in neurons and microglia. The
regulatory network downstream of ROCK is defined by activating
(arrows) or inactivating (blunted arrows) interactions. Induction of
ROCK-activity leads to an up- or down-regulation of downstream
targets, respectively (effects of upregulated ROCK-activity represented by
red arrows). ROCK controls actomyosin contractility (canonical signaling,
green) as well as Akt- and ERK-activity (non-canonical crosstalk, blue).
ROCK-dependent profilin phosphorylation reduces its recycling capacity
for globular (G)-actin leading to decreased turnover between filamentous
(F) and G-actin. Cofilin-phosphorylation inactivates its F-actin severing
activity resulting in less F-actin nucleation. Phosphorylation and
inactivation of myosin light chain phosphatase (MLCP) induces myosin
activity facilitating retrograde flow of F-actin. Together, those changes
lead to a collapsing growth cone and inhibit axonal regeneration
processes (reviewed in Lowery and Van Vactor, 2009; Gomez and
Letourneau, 2014). ROCK phosphorylates and activates PTEN which in
turn inactivates Akt. Similarly, ERK-activity is negatively regulated by
ROCK. Neurotrophic Akt- and ERK-pathways are well described
agonists of neuronal survival. However, also neuronal morphology is
targeted by Akt/ERK signaling thereby influencing neuronal regeneration
processes. The role of ROCK activity in microglia-activation is less
understood. However, cytoskeletal alterations in ROCK-inhibitor treated
cells implicate an involvement of canonical signaling, while
ROCK-crosstalk has not been evaluated in microglia yet.
ROCK-inhibitor, Fasudil, which obtained drug approval by
Japanese authorities for ischemic stroke treatment (Chen et al.,
2013a). Together with the promising results in NDD animal
models this hints for broad neuroprotective effects of ROCK-
inhibition. However, distinct mechanisms are attributable for
that.
Here, we aim to review the current literature of ROCK-
inhibition bringing together different fields of NDDs, thereby
identifying common mechanisms including crosstalk with
other downstream pathways as well as disease specific effects.
Anticipating this, enhanced ROCK-activities have been reported
in many in vitro and in vivo NDD models. Thus, ROCK
inhibition might at least in part exert its beneficial effects
on NDDs by rescuing pathomechanistic changes. Thereby,
two dimensions of elevated ROCK-activity have to be taken
into account: (i) The pathway dimension, and (ii) the cell-
type dimension. (i) Canonical ROCK signaling has been
extensively studied and associated with the control of actomyosin
contractility via phosphorylation of downstream actin-binding
proteins such as cofilin or profilin as well as myosin-binding
proteins such as myosin light chain phosphatase (reviewed in
Gomez and Letourneau, 2014) (Figure 1). In neuronal cells,
globally enhanced ROCK-activity leads to growth cone collapse
indicating a detrimental role in regenerative, outgrowth related
processes (Lowery and Van Vactor, 2009). Despite that, ROCK
negatively controls neurotrophic pathway-signaling, which we
will term “non-canonical ROCK-crosstalk”. Those pathways
involve PTEN, Akt, and ERK acting upstream of neuronal
survival (Lingor et al., 2008; Takata et al., 2013; Hensel et al.,
2014). Thus, enhanced neuronal ROCK activity in NDDs might
inhibit regeneration as well as survival (Figure 1). However,
the mechanisms of the crosstalk still lack a detailed molecular
description.
(ii) In microglia, ROCK-activity is critically involved in
neurodegeneration. Despite microglia, other inflammatory cells
are likely involved in neurodegeneration. However, in the
context of ROCK-inhibition in NDDs microglia have been most
extensively studied. Microglia, also termed “macrophages of the
nervous system”, have ambiguous roles in NDDs dependent
on their activation state (reviewed in Tang and Le, 2015):
Activated M1 microglia represent an early reaction to neuronal
insults ensuring an inflammatory and neurotoxic environment.
However, neurotoxicity might affect healthy neurons inducing
a vicious cycle with chronic neuroinflammation (Tang and
Le, 2015). In contrast, alternatively activated or deactivated
M2-microglia are anti-inflammatory and support tissue and
extracellular matrix repair (Tang and Le, 2015). Interestingly,
ROCK activity is needed to maintain M1-phenotype as
Fasudil-mediated ROCK-inhibition shifts M1-microglia to the
M2-state (Zhang et al., 2013). Moreover, activation of the
microglial ROCK-axis was associated with cytoskeletal changes
and enhanced migration indicating involvement of canonical
ROCK-signaling (Bernhart et al., 2010). Additionally, superoxide
production was increased (Moon et al., 2013). In turn, microglia
express repellents such as chondroitin sulfate proteoglycans
(CSPG) which activate ROCK in neurons, thereby inhibiting
axonal regeneration (Monnier et al., 2003; Koch et al.,
2014). Thus, the benefits of ROCK-inhibition rely on the
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manipulation of cellular and molecular (patho-) mechanisms
which are at least in part shared by all NDDs. Those
mechanisms can be categorized into (i) support of axonal
regeneration, (ii) support of neuronal survival, and (iii)
inhibition of detrimental neuroinflammation. Moreover, we and
others showed that ROCK-inhibition beneficially interferes with
pathological molecular mechanisms specific for a single NDD
(Figure 2).
Parkinson’s Disease (PD)
PD is characterized by a loss of dopaminergic neurons within
the substantia nigra pars compacta leading to an imbalanced
basal ganglia signaling. Clinically, this manifests in severe
motor impairments such as tremor, rigor, bradykinesia, and
postural instability. Although a number of environmental risk
factors have been linked with some cases of sporadic PD,
FIGURE 2 | Beneficial effects of ROCK-inhibition in
neurodegeneration – an integrated model. Neurodegenerative and
neuroinflammatory processes (gray arrows) in different NDDs and in
multiple sclerosis (MS) can be reversed by ROCK-inhibition (green
arrows). Neuronal degeneration in Spinal Muscular Atrophy (SMA),
Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), Parkinson’s
Disease (PD), and Huntington’s Disease (HD) lead to a microglia-intrinsic
ROCK-induction necessary for microglia-activation. Activated microglia
form engulfing “gliapses” with degenerating neurons subsequently
phagocytosing neuronal debris. Moreover, they secret factors, which
activate ROCK in neurons, thereby inhibiting axonal regeneration.
Activated microglia can enter a “vicious circle” of chronic
neuroinflammation attacking healthy neurons leading to neuronal
degeneration and death. In MS, chronic neuroinflammation might be
induced by microglia-activation and Blood-Brain Barrier (BBB) breakdown.
ROCK-inhibition interferes with different pathomechanistic alterations in
NDDs (green arrows). Down-regulation of ROCK-hyper-activity in microglia
leads to their inactivation, while neuron-intrinsic ROCK-inhibition triggers
axonal regeneration via canonical ROCK-signaling controlling actomyosin
contractility. Additionally, ROCK-inhibition activates neurotrophic
pathway-signaling via non-canonical crosstalk leading to a neuronal
rescue. Besides those general effects, ROCK-inhibition specifically
interferes with disease-specific molecular pathomechanisms. In AD and
HD, neuronal aggregate toxicity is attenuated by ROCK-inhibition, while
cytoskeletal dysregulations involving profilin represent the underlying
mechanism in SMA.
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the vast majority still remains of unknown etiology (reviewed
in Schiesling et al., 2008). Beside these idiopathic PD cases,
several genes have been identified to be involved in familial
Parkinsonism. Among those, alpha-synuclein was the first to
be identified (Polymeropoulos et al., 1997). Together with
autosomal dominant point mutations, gene multiplications of
wild-type alpha-synuclein have been linked to an enhanced
susceptibility for PD (Singleton et al., 2003; Nishioka et al.,
2006). The latter argues for a pathological gain of function
mechanism. Interestingly, alpha-synuclein is also a major
component of Lewy bodies (LBs) (Spillantini et al., 1997). LBs
are neuronal cytoplasmic protein aggregates found in surviving
neurons post mortem and represent a central pathological
hallmark of idiopathic PD (Gibb and Lees, 1989). This hints
for alpha-synuclein as a common pathomechanistic internode
in PD-etiology. Supporting this, toxin-induced dopaminergic
neurodegeneration, classically employed as PD model, is
dependent on alpha-synuclein abundance: Knock-out mice
were resistant to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrine
(MPTP)-induced toxicity of dopaminergic cells (Dauer et al.,
2002). Importantly, mutant alpha-synuclein transduced neuronal
cultures as well as MPTP-based in vivomodels displayed a hyper-
active ROCK-signaling axis, emphasizing ROCK-upregulation as
a common mechanism of genetic and toxin-induced PD-models
(Barcia et al., 2012; Villar-Cheda et al., 2012; Tonges et al., 2014b).
Such toxin-induced rodent models have also been extensively
employed to study the impact of ROCK-inhibition on clinically
relevant outcomes in PD (Barcia et al., 2012; Tonges et al., 2012,
2014b; Tatenhorst et al., 2014; Saal et al., 2015). The severity
of dopaminergic neuron damage might thereby be critical for
the success of ROCK inhibition: While severely lesioned 6-
hydroxy dopamine (6-OHDA) animals did not respond to
oral Fasudil-application with respect to dopaminergic neuron
numbers or motor-phenotype (Tatenhorst et al., 2014), the less
severe MPTP-mouse displayed a partial rescue of dopaminergic
neuron numbers within the substantia nigra, a partial rescue of
TH-fiber density as well as motor-behavior (Tonges et al., 2012).
Moreover, an up-regulation of the activity of the pro-survival
Akt-pathway was reported in response to co-application with
MPP+, the toxic MPTP-metabolite, and Fasudil in vitro (Tonges
et al., 2012). As the MPTP-model displays an axonal dying-
back pathology preceding neuronal demise (Li et al., 2009a),
the authors suggested a dual impact of ROCK-inhibition on (i)
axonal regeneration supported by (ii) induction of pro-survival
pathways. The first might thereby be mediated by canonical
ROCK-signaling controlling actomyosin contractility at the tip of
the regenerating axon while the latter might be dependent upon
non-canonical ROCK-crosstalk partners such as Akt.
In general, such non-canonical crosstalk is not restricted to
Akt, but seems to involve neurotrophic signaling more broadly:
In vitro and in vivo results demonstrated increased activities
of STAT3, ERK, and Akt – classical neurotrophic pathways
– when treated with ROCK-inhibitor Y27632. Importantly,
these crosstalk were dependent on neurotrophic pathway
activation as they could only be detected under co-treatment
with neurotrophic factors such as Ciliary Neurotrophic Factor
(CNTF) or Fibroblast Growth Factor 1 and 2 (FGF1, FGF2)
(Lingor et al., 2008; Lin et al., 2009; Hensel et al., 2014).
Additionally, we could show that the crosstalk between
ROCK and ERK is bi-directional which might have important
implications for the pathological situation in NDDs in general:
Enhanced neuronal ROCK-activities in NDDs might not
only hamper axonal regeneration via changed acto-myosin
contractility but also shift neurons toward pro-apoptotic
signaling (Hensel et al., 2014).
Interestingly, MPTP-induced reduction of TH+-cell numbers
were also partially rescued in primary neuron/glia cultures
by application of the ROCK-inhibitor Y27632 while there
was no effect on pure neuronal cultures. In contrast, Y27632
was able to rescue neurite lengths independent of microglia
abundance (Borrajo et al., 2014). This points toward cell-type
specific beneficial roles of ROCK inhibition in PD: Supporting
axonal regeneration via neuron-intrinsic pathways as well as
inhibition of dopaminergic neuron loss via microglia-dependent
mechanisms. The importance of microglia as a target for ROCK-
inhibition in PDhas been further underlined asMPP+-treatment
led to an enhanced ROCK-activity in glia-cells in vitro (Villar-
Cheda et al., 2012). Accordingly, MPTP-treatment induced
microglial activation leading to an increase in contacts between
microglia and dopaminergic neurons in vivo (Barcia et al., 2012).
Those contacts, displayed distinct morphological properties
with F-actin clusters polarized toward the microglia-neuron
contact side engulfing degenerating neurons, similar to the
immunological synapse – therefore termed “gliapse” by the
authors (Barcia et al., 2012). Importantly, application of Fasudil
completely prevented microglial activation and fully rescued
TH+-cell numbers (Barcia et al., 2012). However, it is still
possible that the in vivo rescue of dopaminergic neurons is at
least in part neuron-intrinsicallymediated by non-canonical anti-
apoptotic pathways such as Akt or ERK. Supporting this, an
AAV2-mediated knock-downof ROCK2, preferentially expressed
in neurons, induced ERK-activity in vitro, partially rescued the
number of TH+-cells andmildly improved themotor-phenotype
in vivo (Saal et al., 2015). A cell-type-specific ROCK-inhibition in
microglia or neurons would therefore be an interesting approach
to further clarify the detrimental contribution of microglia versus
neuron-intrinsic ROCK-activity in PD.
Multiple Sclerosis (MS)
MS is a clinically diverse chronic CNS-disease characterized by
inflammatory cell plaques in the white matter, loss of myelin
and oligodendrocytes as well as gliosis (reviewed inGoldenberg,
2012; Duffy et al., 2014). The etiology of MS is largely unknown.
However, together with histopathological findings, genetic risk
factors such as variations of the major histocompatibility
complex (MHC) (International Multiple Sclerosis Genetics et al.,
2011) argue for an important role of neuroinflammation. Blood
brain barrier (BBB) breakdown with infiltrating peripheral
immune-cells is a characteristic event in the natural history
of MS (reviewed in Ortiz et al., 2014). Interestingly, microglia
are activated in advance of peripheral immune cell infiltration,
underlining the importance of these cells in MS-disease
progression (Ponomarev et al., 2005). Alternatively, it was
Frontiers in Neuroscience | www.frontiersin.org 4 June 2015 | Volume 9 | Article 198
Hensel et al. Rho-kinase (ROCK) inhibition in neurological disorders
suggested that MS is in fact a degenerative disorder (reviewed
in Stys et al., 2012) which is supported by axonal damage not
exclusively occurring in areas affected by auto-immunity (Trapp
et al., 1998). At least, those axonal transections point toward a
neurodegenerative component in MS-pathology.
Experimental autoimmune encephalomyelitis (EAE) has
been extensively employed as an MS-animal model. Auto-
immunization with myelin-sheet protein components such as
myelin, oligodendrocyte glycoprotein (MOG), or Proteolipid
Protein (PLP) induces pathological features similar to MS
including neuroinflammation, demyelination, and neuronal
damage (reviewed in Baxter, 2007). Importantly, ROCK
upstream effector RhoA was upregulated in MS-patient plaques
(Tajouri et al., 2005), and a PLP-induced EAE-mouse model
exhibited an enhanced ROCK-activity in the CNS (Sun et al.,
2006). Consistently, Fasudil application either in a preventive or
therapeutic paradigm reduced clinical severity in different EAE-
models (Sun et al., 2006; Hou et al., 2012). This was accompanied
by a reduction of infiltrating inflammatory cells, demyelinated
areas, and axonal transactions. Moreover, immune cells isolated
from Fasudil-treated mice exhibited a decreased potential for
immune response against EAE-inducing antigen, indicating a
major role of ROCK-activity in mediation of auto-immunity
by inflammatory cells (Sun et al., 2006). However, a chronic
disease like MS demands long-term treatments with a minimal
amount of side-effects. Thus, alternative application routes
combining high CNS-availability with low peripheral abundance
are favorable. Interesting results in this context were obtained by
intranasal delivery of a Fasudil-derivate in a MOG-induced EAE
mousemodel (Li et al., 2014b). This treatment-regimen efficiently
reduced demyelination, improved clinical scores, and enhanced
body weight. Besides a reduction of neuroinflammation, the
authors reported elevated BDNF- and NGF-levels suggesting
an involvement of neurotrophic pathways by a yet unknown
mechanism (Li et al., 2014b). However, this co-occurrence of
neurotrophic factor-expression and ROCK-inhibition suggests
an induction of pro-survival signals by non-canonical ROCK-
crosstalk. Therefore, it is possible that beneficial effects of
ROCK-inhibition in EAE are not only based on inhibition of
neuroinflammation but are also mediated neuron-intrinsically.
Alzheimers Disease (AD)
The central clinical manifestations of AD are progressive
cognitive deficits, namely memory, and learning disabilities.
The neuropathological picture includes hippocampal atrophy
with neuronal loss and reduced synaptic contacts. However, the
characteristic histological findings defining AD are extracellular
senile plaques and intraneuronal neurofibrillary tangles
(reviewed in Perl, 2010). While the first is composed of amyloid-
β (Aβ) peptides, the latter consists of hyper-phosphorylated
tau-protein (reviewed in Bloom, 2014). The causal nature of Aβ-
pathology is still under debate and findings of Aβ-accumulations
without clinical manifestations question a strict relationship
between Aβ-plaques formation and AD-symptoms for late-onset
sporadic AD (reviewed in Moreno-Trevino et al., 2015). In
contrast, mutations in the amyloid precursor protein (APP) as
well as in presenilin 1 and 2 (PSEN1, 2) which participate in
APP-processing cause hereditary early onset AD (Selkoe, 2001;
Haass et al., 2012). This hints for an etiology based on Aβ-
synthesis and secretion pathways. Thus, idiopathic and familial
AD might differ in etiology, however, idiopathic AD-brains
display enhanced neuronal ROCK2-protein levels (Herskowitz
et al., 2013) as well as an altered subcellular distribution of its
upstream effector RhoA which is a characteristic in common
with genetic AD-mouse models (Huesa et al., 2010). Moreover,
several studies demonstrated a role of the ROCK-pathway in
Aβ-synthesis and secretion (Zhou et al., 2003; Herskowitz et al.,
2013). Thus, the ROCK-pathway is a common target for both,
idiopathic and familiar AD.
Intracerebroventricular Aβ-injections in rats lead to severe
cognitive impairments, neuronal damage and an inflammatory
response (Song et al., 2013) and can be employed as an AD-
model reflecting Aβ-downstream effects. Interestingly, Fasudil-
application rescued spatial learning and memory deficits as well
as apoptosis phenotype in the AD-rat hippocampus. Moreover,
inflammatory response indicated by enhanced IL-1β, TNFα,
and NFκB-production was reduced back to normal levels (Song
et al., 2013). Those effects might be mechanistically attributable
to an inhibition of neuroinflammation or to an induction of
anti-apoptotic neurotrophic pathways via non-canonical ROCK-
crosstalk partners; however, the latter has not been tested in this
AD-model yet.
Despite its action on neuroinflammation, several studies
revealed a direct molecular role of the ROCK pathway
within the Aβ-biosynthesis pathway. Plasma membrane
bound APP is subjected to the non-amyloidogenic pathway
by α-secretase cleavage leading to non-toxic sAPPα. When
internalized, APP can be subsequently cleaved by β-secretase
BACE1 and γ-secretase leading to toxic Aβ-production of
different peptide lengths (reviewed in Bu, 2009). Importantly,
Y27632-mediated ROCK inhibition changes γ-secretase
cleavage specificity thereby shifting toxic Aβ1−42-peptide
production to Aβ1−38 (Zhou et al., 2003), which is less toxic
and might even be protective in combination with Aβ1−42
(Vandersteen et al., 2012). However, total Aβ-production was
not changed. Interestingly, ROCK-isoforms differentially act
on the amyloidogenic pathway: While ROCK1 knock-down
enhances total Aβ-production in vitro, ROCK2 inhibition by
the isoform-specific compound SR3677 reduced total Aβ-levels
in vitro and in vivo (Herskowitz et al., 2013). Mechanistically,
the authors suggested a regulation of BACE1-activity by
ROCK2-mediated phosphorylation in combination with
ROCK2-mediated APP phosphorylation triggering its processing
(Herskowitz et al., 2013). In summary, ROCK-inhibition
demonstrated efficacy in an AD-rat model most probably
by inhibiting neuroinflammation. However, ROCK2-specific
inhibition might be even more promising specifically targeting
amyloidogenic pathways. In this context, ROCK1-inibition
even might have a detrimental effect by enhancing Aβ levels.
Thus, beneficial effects of global ROCK inhibition reducing
neuroinflammation but enhancing Aβ biosynthesis via ROCK1
have to be trade-off against a specific ROCK2-inhibition without
targeting glial cells.
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Huntington’s Disease (HD)
HD is a hereditary neurodegenerative disease caused by CAG-
repeats within the huntingtin (Htt)-gene (The Huntington’s
Disease Collaborative Research Group, 1993). Thereby, the
number of CAG-repeats correlates with the clinical onset
which typically manifests by involuntary movements, and
increasing motor- and cognitive dysfunctions. Consistent with
the clinical picture, neuronal subpopulations display a selective
vulnerability in HD with atrophy and neuronal degeneration
in basal ganglia and cortex (reviewed in Shoulson and Young,
2011). The exact mechanism of neurodegeneration still remains
unknown. However, mutant huntingtin aggregates or oligomers
within neurons might play a crucial role (Legleiter et al.,
2010).
Interestingly, the ROCK-pathway is directly involved in
mutant huntingtin degradation and aggregate formation:
Y27632 enhanced Htt-degradation thereby reducing its
aggregation in vitro (Bauer et al., 2009), possibly by proteasome-
activation and macroautophagy (Bauer and Nukina, 2009).
Moreover, Htt aggregation is facilitated by ROCK-dependent
phosphorylation of vimentin which finally leads to enhanced
levels of free IP3R1. As IP3R1 facilitates mutant htt-aggregation,
the authors proposed a model where ROCK-inhibition inhibits
htt-aggregation via vimentin-IP3R1 axis (Bauer et al., 2011,
2012). Alternatively, a mechanism based on a direct molecular
interaction of Htt was proposed: The ROCK-downstream target
profilin-1, an actin binding protein and a major regulator
of actin-dynamics, as well as the neuronal isoform profilin-
2a, directly interact with huntingtin (Goehler et al., 2004;
Shao et al., 2008). This interaction prevented Htt-aggregation
indicating a beneficial effect in HD. Importantly, ROCK-
mediated phosphorylation of profilin at Serine-137 inhibited
its aggregation suppressing activity, suggesting beneficial
effects of ROCK-inhibition in HD mediated by profilin-
dephosphorylation (Shao et al., 2008). Consistently, Y27632
partially rescued photoreceptor neurons in a HD-Drosophila
model (Pollitt et al., 2003). However, ambiguous results were
obtained in R6/2 HD-model mice. Y27632 only mildly improved
motor-performance, but had no effect on lifespan, cellular
atrophy or aggregate formation (Li et al., 2009b). This lack
of effects might be due to an insufficient dosing-regimen as
there was no impact on profilin-phosphorylation (Li et al.,
2009b). Intravitreal Fasudil application in the same model
reduced retinal phospho-profilin1 staining and partially
rescued retinal dysfunction (Li et al., 2013). Although retinal
dysfunction might not be a feature of HD (Petrasch-Parwez
et al., 2005), ROCK inhibition therefore proofed its beneficial
potential on the functional level. However, mechanisms
underlying those effects remain unclear as Htt-aggregation
state, neuroinflammation, neuronal survival, or axonal
regeneration have not been measured in a ROCK-inhibited
HD-mouse model yet. Interestingly, neuronal survival and
axonal regeneration in a primary HD in vitro-model could
both be rescued by ROCK-inhibition (Deyts et al., 2009)
suggesting the inclusion of such outcomes in future in vivo
studies.
Spinal Muscular Atrophy (SMA)
SMA is a monogenic motoneuron-disease affecting lower
motoneurons progressively leading to paralysis, muscle atrophy
and –in severe cases– to death. SMA is caused by deletions
or loss-of-function mutations of the survival of motoneuron 1
(Smn1)-gene (Lefebvre et al., 1995). Humans harbor a second
gene, Smn2, coding for the same protein. However, only low
amounts of functional full-length protein is expressed from Smn2
(Lorson et al., 1999). While complete SMN-loss is embryonically
lethal, low SMN-levels lead to SMA and consistently, the number
of Smn2-gene copies inversely correlates with disease severity
(Taylor et al., 1998). The SMN-protein is ubiquitously expressed,
and not surprisingly severe SMA with low SMN levels is
considered not to be of pure motoneuron-pathology rather than
being a multi-system disorder (Shababi et al., 2014). However,
motoneurons are still preferentially affected, arguing in favor of
focusing on pathomechanisms specific for these cell-types. The
role of ROCK in SMA in different cellular contexts has been
extensively studied and already excellently reviewed (Coque et al.,
2014), so that we will address this only at a glance.
Importantly, ROCK-activity is enhanced in SMA-mouse
model spinal cords and inhibition of ROCK by Y27632 or
Fasudil significantly enhanced survival, rescued neuromuscular
junction (NMJ) morphology, and muscle atrophy (Bowerman
et al., 2010, 2012). Consistently, neuronal SMA-in vitro models
displayed an hyper-active ROCK-signaling axis, indicating a
neuron-intrinsic mechanism (Bowerman et al., 2007; Nolle et al.,
2011; Hensel et al., 2014). Based on a direct interaction of the
SMN-protein with the ROCK-downstream target profilin2a, the
neuronal profilin-isoform, we proposed a molecular mechanism
of neurotoxicity induced by SMN-depletion (Nolle et al., 2011):
SMN-reduction leads to changed profilin2a-homeostasis and
an enhanced profilin2a-ROCK binding. This finally results
in a hyper-phosphorylation of profilin2a and a sequestration
of ROCK from other downstream-targets such as cofilin or
myosin light chain phosphatase (MLCP). Accordingly, those
ROCK-targets were hypo-phosphorylated and actin-composition
changed towards more stable, less dynamic, filamentous (F) actin
(Nolle et al., 2011). This might have important implications for
neuronal motility processes based on actomyosin contractility.
Accordingly, neurite outgrowth defects were reported in SMA
in vitro models (Van Bergeijk et al., 2006; Nolle et al., 2011).
However, involvement of other actin-based motility processes
such as axonal transport or synaptic vesicle cycling is possible.
In this model, beneficial effects of ROCK-inhibition are mainly
mediated by reduced phosphorylation of neuronal profilin,
however, positive effects on gliosis which is a well-known feature
of SMA (Simic, 2008) is likely possible.
Besides an up-regulated ROCK-pathway, also the ERK-
signaling axis is hyper-activated in SMAmodel mice spinal cords
(Branchu et al., 2013). In contrast to the classical view of ERK as
an anti-apoptotic, neurotrophic pathway this over-activation acts
detrimental on SMA-phenotype as ERK-inhibition by the small
inhibitor Selumetinib enhanced survival of SMA-mice (Branchu
et al., 2013). Therefore, the authors suggested an SMA-specific
mechanism based on elevated SMN-expression. According to
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the in vivo situation, we could confirm ERK hyper-activation
in motoneuron-like cells in vitro (Hensel et al., 2012, 2014).
Moreover, ROCK and ERK are bi-directionally linked, as ROCK
inhibits ERK and vice versa (Hensel et al., 2014). This crosstalk
was observed in a timeframe of minutes making it unlikely
that expressional changes represent the underlying mechanism.
Interestingly, the crosstalk became uni-directionalized in SMA-
model cells, as ERK was not capable to down-regulate ROCK
selectively in SMA-cells. In summary, this leads to a co-
hyperactivation of the ROCK- and ERK-signaling axes in SMA-
cells (Hensel et al., 2014). As both pathways are potential
therapeutic targets, we suggested a ROCK, ERK co-inhibition
using a combination of Fasudil and Selumetinib. As detrimental
ERK-hyper-activation could potentially be enhanced by ROCK-
inhibition via ROCK-ERK crosstalk, we even expect synergistic
effects of a combined treatment approach (Hensel et al., 2014).
Another crosstalk partner of ROCK is the phosphatase
and tensin homologue deleted on chromosome ten (PTEN).
PTEN mainly antagonizes the phosphatidylinositol 3 kinase
(PI3K) pathway by hydrolyzing the second messenger
phosphatidylinositol (3,4,5)-triphosphate (PIP3) thereby
blocking the recruitment and activation of Akt (reviewed in
Song et al., 2012; Hopkins and Parsons, 2014). It was shown that
ROCK directly interacts and phosphorylates PTEN at several
sites (Li et al., 2005; Hopkins et al., 2014). In non-neuronal
cells, activated ROCK1 induced PTEN-activity resulting in
an inactivation of Akt (Li et al., 2014a). Interestingly, in vitro
data revealed that ROCK2, the neuronal ROCK-isoform, more
potently phosphorylates PTEN than ROCK1 (Song et al., 2009).
Thus, neuron-intrinsic ROCK-Akt crosstalk might be mediated
via PTEN and enhanced ROCK-activities in SMA might lead
to reduced Akt-activation via PTEN. However, while reduced
Akt-activation has been pre-symptomatically observed in
SMA-mice spinal cords (Branchu et al., 2013), to our knowledge,
PTEN activity has not been monitored in SMA models so far.
Importantly, increasing evidence has occurred about the role of
PTEN in SMA: Knock-down of PTEN in cultured motoneurons
as well as in SMA mice increases activity of the Akt-pathway,
decreases disease severity and moderately enhances survival of
SMA mice (Ning et al., 2010; Little et al., 2015).
Amyotrophic Lateral Sclerosis (ALS)
ALS is a motoneuron disease not only affecting lower
motoneurons in spinal cord but also leading to upper
motoneuron and brainstem degeneration. Clinical symptoms
include muscle weakness and paralysis leading to death 3–5
years after onset, which typically develops in advanced adulthood
(reviewed in Chen et al., 2013b). About 90% of cases are sporadic
with an unknown etiology; however, several risk genes with
different penetrance have already been identified (Chen et al.,
2013b). Mutant Superoxide dismutase 1 (SOD1) was the first
gene identified to be involved in familiar ALS (Rosen, 1993), and
the high penetrance allele SOD1G93A (Synofzik et al., 2010) has
been employed to generate the most extensively used ALS-mouse
model (Gurney, 1997).
Interestingly, SOD1G93A-mice exhibited an enhanced ROCK-
activity, elevated PTEN-activity while the Akt-pathway was
down-regulated. Moreover, ROCK-inhibition by Fasudil-
treatment completely rescued PTEN/Akt activity (Takata
et al., 2013). This was accompanied by delayed symptom
onset, enhanced survival and a partial rescue of motoneuron-
numbers within spinal cord of SOD1G93A-mice (Takata
et al., 2013). Interestingly, Fasudil-application in another
study not only enhanced survival but also motor functions
in SOD1G93A-mice. Moreover, motoneuron degeneration
and nerve fibers were partially rescued (Tonges et al.,
2014a). While the numbers of astroglial cells was reduced,
Fasudil-treatment further enhanced microglia cell numbers
but shifted morphology to the beneficial M2-microglia
mechanism (Tonges et al., 2014a), which is in accordance
with in vitro data (Zhang et al., 2013). Thus, two different
studies suggested different mechanisms underlying beneficial
effects of ROCK-inhibition in ALS-mouse models: (i) Altering
the microglia-subtype composition, or (ii) inducing anti-
apoptotic signaling via non-canonical ROCK-crosstalk.
However, also neuron-intrinsic canonical ROCK-signaling,
controlling axonal regeneration, is a candidate-mechanism.
Involvement of ROCK-pathway and actin-dynamics in
ALS-pathogenesis has recently been supported by newly
identified familial ALS-genes: Mutations in the profilin1-
gene are associated with high risks to develop ALS (Wu
et al., 2012). Among those, profilin1T109M represents
a phospho-site mutation (Ingre et al., 2013) indicating
an important role of profilin-phosphorylation However,
it is unclear whether ROCK is an upstream-kinase for
this site.
Summary and Future Perspectives
Taken together, ROCK-inhibition ameliorates clinically relevant
outcomes in rodent models of several NDDs making it a
promising future treatment-strategy. However, with regard to
chronic diseases detrimental long-term effects have to be
considered highlighting alternative approaches such as non-
systemic application routes as well as ROCK-isoform specific
inhibition. With regard to the underlying mechanisms, neurons
as well as neuroinflammatory cells such as microglia seem to be
involved in mediating the beneficial effects of ROCK-inhibition.
Genetic models with cell specific ROCK-depletion would greatly
improve our understanding of the exact contribution by
different cell-types. Moreover, little is known about the ROCK-
dependent activation-mechanisms of neuroinflammatory cells on
the molecular level. While ROCK-crosstalk with neurotrophic
pathways is a relevant mechanism in neurons, such mechanisms
have not been demonstrated in microglia yet. At this point, it
has to been considered that elucidiation and analyses of single
pathways and crosstalking molecules may limit our view on
regulatory mechanisms. Instead, future work has to determine
important nodes and edges as basic components of a molecular
network with ROCK at its center. For example, network analyses
could reveal new feedback loops and other network motifs
relevant to determine direct and indirect effects of inhibitory
drugs. Such a network should include multi-dimensional data on
expression as well as on activation states to truly understand the
flow of information in physiological and diseased conditions.
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